Catalent (CTLT) Shares are Down -3.22%

Catalent (CTLT) has risen sharply, recording gains of 2.38% in the past 4 weeks. However, the stock has corrected -3.22% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 2.93% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 1.99% and the 50-Day Moving Average is 2.62%.The 200 Day SMA reached 2.45%


Catalent (NYSE:CTLT): After opening at $25.66, the stock dipped to an intraday low of $25.61 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $26.03 and the buying power remained strong till the end. The stock closed at $25.84 for the day, a gain of 0.94% for the day session. The total traded volume was 1,849,444. The stocks close on the previous trading day was $25.84.

Catalent (CTLT) : The most positive equity analysts on Catalent (CTLT) expects the shares to touch $30, whereas, the least positive believes that the stock will trade at $23 in the short term. The company is covered by 5 Wall Street Brokerage Firms. The average price target for shares are $27 with an expected fluctuation of $2.65 from the mean.

Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.